1-5 of 5
naphthyridines
Close
Sort by
Journal Articles

Multiple Myeloma-Specific Targeted Therapy: Use of the Tumor Specific Immunoglobulin Gene Sequence to Activate Drugs Only within Tumor Cells.

Zhi-Wei Li, PhD, Dror Shalitin, PhD, Jennifer Finefield, Crystal Leung, Mengyin Hu, Jing Shen, Mingjie Li, Cathy S Wang, Jeffrey A Steinberg, Eric Sanchez, Haiming Chen, MD, PhD, Robert M Williams, PhD, Benjamin Bonavida, PhD, James R. Berenson, MD
Journal: Blood
Blood (2009) 114 (22): 1851.
https://doi.org/10.1182/blood.V114.22.1851.1851
Published: 2009
Journal Articles

An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis

Roland E. Kälin, Nadja E. Bänziger-Tobler, Michael Detmar, André W. Brändli
Journal: Blood
Blood (2009) 114 (5): 1110–1122.
https://doi.org/10.1182/blood-2009-03-211771
Published: 2009
Includes: Supplemental data
Journal Articles

A Phase 1 Dose-Escalation Study of the Novel Cell Cycle Active Agent SNS-595 in Advanced Leukemias.

Jeffrey E. Lancet, MD, Judith E. Karp, MD, Nancy Havrilla, Ute Hoch, PhD, Jeffrey Silverman, PhD, Daniel Adelman, MD, Francis J. Giles, MD
Journal: Blood
Blood (2006) 108 (11): 1962.
https://doi.org/10.1182/blood.V108.11.1962.1962
Published: 2006
Journal Articles

SNS-595 a Novel S Phase Active Cytotoxic Acts Synergistically with Cytarabine To Reduce Bone Marrow Cellularity and Circulating Neutrophils.

Jennifer Arbitrario, BS, Jeffrey Kumer, MS, Anthony Howlett, Ph.D., Jeffrey Silverman, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2321.
https://doi.org/10.1182/blood.V108.11.2321.2321
Published: 2006
Journal Articles

SNS-595, a Novel S-Phase Active Cytotoxic, Demonstrates Pharmacologic Properties Appropriate for the Treatment of Advanced Hematologic Malignancies.

Chris E. Lawrence, BS, PhD, Jen P. Arbitrario, BS, Jeff L. Kumer, BS, MS
Journal: Blood
Blood (2005) 106 (11): 4632.
https://doi.org/10.1182/blood.V106.11.4632.4632
Published: 2005